

Corporate Overview

XTENT, Inc. (Nasdaq:XTNT) is a publicly traded medical device company dedicated to developing and commercializing customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD).

Customizable Drug Eluting Stent (DES) Approach

The XTENT[®] Custom NX[®] DES system is designed to offer personalized care to today's CAD patients, and to benefit those delivering their care by improving efficacy and efficiency while reducing costs.

Custom NX[®] DES System

The first customizable drug eluting stent system, Custom NX DES allows physicians to:

- Customize the length and diameter of the stent once inside the artery
- Treat single, multiple, or long lesions with one device, whereas the current generation DES would require multiple stents, balloons and catheter exchanges

The system is designed to address the limitations and potential safety concerns of today's current generation drug eluting stents. The design of the Custom NX includes a flexible "interdigitated" stent that can be "custom-sized" based on the length of the patient's lesion, a sheath protected delivery system to improve deliverability, and a biodegradable drug carrier.

CUSTOM Clinical Program

XTENT has presented promising results from three clinical trials, CUSTOM I, CUSTOM II, and CUSTOM III, which evaluate the use of the Custom NX DES system in single, multiple, and long lesions.

Market Opportunity

XTENT's customizable stent technology addresses a market worth more than \$4 billion worldwide. In 2007, drug eluting stents were used exclusively in 65% of all stent procedures in the United States and 53% of stent procedures worldwide (including the US)¹.

¹ Millennium Research Group

LEADERSHIP

Management Team

Gregory D. Casciaro
President & Chief Executive Officer

Timothy D. Kahlenberg
Chief Financial Officer

Randolph E. Campbell
Chief Technical Officer

Bernard H. Andreas
Vice President, Innovation & Concept Development

Anne-Marie Hodkinson
Vice President, Human Resources

Philippe H. Marco, M.D.
Vice President, Quality Assurance, Clinical and Regulatory Affairs

Board of Directors

Henry A. Plain, Jr.
Chairman of the Board

Michael A. Carusi

Gregory D. Casciaro

Michael L. Eagle

Robert E. Flaherty

Christopher M. Smith

Arthur T. Taylor

Edward W. Unkart

Allan R. Will

For more information contact:

Danielle Bertrand
WeissComm Partners
415-946-1056
dbertrand@weisscommpartners.com